

Niraparib PRIMA/ENGOT-OV26/COG-3012

### PRELIMINARY SCORE

#### CURATIVE



#### NON-CURATIVE



### ADJUSTMENTS

#### Quality of life



No QoL benefit



#### Serious and disabling adverse effects



#### Other adjustments



Niraparib PRIMA/ENGOT-OV26/COG-3012

### SCORE

#### CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response


#### NON-CURATIVE



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

#### INFORMATION

Tumour type: Gynaecological Malignancies

Therapeutic Indication: Maintenance treatment for patients with advanced epithelial high-grade ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based ChT

Experimental Arm: Niraparib

Control Arm: Placebo



